PDF(Pubmed)
Abstract：
The development of human papillomavirus (HPV) vaccines has made substantive progress, as represented by the approval of five prophylactic vaccines since 2006. Generally, the deployment of prophylactic HPV vaccines is effective in preventing newly acquired infections and incidences of HPV-related malignancies. However, there is still a long way to go regarding the prevention of all HPV infections and the eradication of established HPV infections, as well as the subsequent progression to cancer. Optimizing prophylactic HPV vaccines by incorporating L1 proteins from more HPV subtypes, exploring adjuvants that reinforce cellular immune responses to eradicate HPV-infected cells, and developing therapeutic HPV vaccines used either alone or in combination with other cancer therapeutic modalities might bring about a new era getting closer to the vision to get rid of HPV infection and related diseases. Herein, we summarize strategies for the development of HPV vaccines, both prophylactic and therapeutic, with an emphasis on the selection of antigens and adjuvants, as well as implications for vaccine efficacy based on preclinical studies and clinical trials. Additionally, we outline current cutting-edge insights on formulation strategies, dosing schedules, and age expansion among HPV vaccine recipients, which might play important roles in addressing barriers to vaccine uptake, such as vaccine hesitancy and vaccine availability.
摘要：
人乳头瘤病毒(HPV)疫苗的研制取得了实质性进展,自2006年以来批准了五种预防性疫苗。一般来说,预防性HPV疫苗的部署可有效预防新获得的感染和HPV相关恶性肿瘤的发生.然而,预防所有HPV感染和根除已确定的HPV感染还有很长的路要走，以及随后进展为癌症。通过掺入更多HPV亚型的L1蛋白优化预防性HPV疫苗，探索增强细胞免疫反应的佐剂，以根除HPV感染的细胞，开发单独使用或与其他癌症治疗方式联合使用的治疗性HPV疫苗可能会带来一个新时代，更接近摆脱HPV感染和相关疾病的愿景。在这里，我们总结了HPV疫苗的开发策略，预防和治疗，强调抗原和佐剂的选择，以及基于临床前研究和临床试验对疫苗效力的影响。此外,我们概述了当前关于制定战略的前沿见解，给药时间表，和HPV疫苗接种者的年龄扩大，这可能在解决疫苗摄取障碍方面发挥重要作用，如疫苗犹豫和疫苗供应。
